2020
DOI: 10.1007/s40618-020-01246-0
|View full text |Cite
|
Sign up to set email alerts
|

Long-acting pasireotide improves clinical signs and quality of life in Cushing’s disease: results from a phase III study

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
2

Citation Types

0
23
0

Year Published

2020
2020
2024
2024

Publication Types

Select...
7
1
1

Relationship

0
9

Authors

Journals

citations
Cited by 18 publications
(23 citation statements)
references
References 31 publications
0
23
0
Order By: Relevance
“…A decrease in plasma ACTH and LNSC levels was observed in both cohorts at month 12, and changes in serum cortisol concentrations were generally consistent with plasma ACTH and LNSC concentrations (32). Regarding clinical profile, after 12 months of treatment, a decrease in body weight, waist circumference, and blood pressure was observed, together with an improvement in quality of life (32,33). Moreover, in patients with evaluable measurements at pituitary MRI at both baseline and month 12, a median tumor shrinkage of 17.8% was observed in the 35 patients of 10 mg group and of 16.3% in the 38 patients of 30 mg group; in particular, a decrease in tumor volume ≥20% compared with baseline volume occurred in 15 (43%) of the 35 patients of 10 mg group and in 18 (47%) of the 38 patients of 30 mg group (32).…”
Section: Pasireotidementioning
confidence: 54%
“…A decrease in plasma ACTH and LNSC levels was observed in both cohorts at month 12, and changes in serum cortisol concentrations were generally consistent with plasma ACTH and LNSC concentrations (32). Regarding clinical profile, after 12 months of treatment, a decrease in body weight, waist circumference, and blood pressure was observed, together with an improvement in quality of life (32,33). Moreover, in patients with evaluable measurements at pituitary MRI at both baseline and month 12, a median tumor shrinkage of 17.8% was observed in the 35 patients of 10 mg group and of 16.3% in the 38 patients of 30 mg group; in particular, a decrease in tumor volume ≥20% compared with baseline volume occurred in 15 (43%) of the 35 patients of 10 mg group and in 18 (47%) of the 38 patients of 30 mg group (32).…”
Section: Pasireotidementioning
confidence: 54%
“…203 At month 12, improvements in blood pressure were greater in those with normalized UFC; BMI, weight, waist circumference, and QoL were all improved regardless of UFC control. 204 Longterm extension studies showed that biochemical and clinical improvements could be maintained for up to five years in select patients who continued the study. 205,206 Of note, in real-life settings, limited data are available on long-term treatment compliance, and several studies show a high rate of treatment discontinuation.…”
Section: Pasireotidementioning
confidence: 99%
“…The reduced expression of Sstr2 as a result of GC exposure could have implications for the efficacy of this treatment, as well as the selection of patients most likely to benefit. 41 Aplr, the apelin receptor is of interest because apelin is a stimulator of ACTH release and steroidogenesis, 42,43 and these data suggest a direct role within the pituitary. The transporter Slc12a5, (also known as KCC2) was also up-regulated by DEX; the transporter is inhibited by loop diuretics, and in vitro has been shown to inhibit ACTH release.…”
Section: Discussionmentioning
confidence: 99%
“…Sstr2 , the somatostatin 2 receptor is a target of pasireotide, which is being trialled for use in treatment of Cushing's disease. The reduced expression of Sstr2 as a result of GC exposure could have implications for the efficacy of this treatment, as well as the selection of patients most likely to benefit 41 . Aplr , the apelin receptor is of interest because apelin is a stimulator of ACTH release and steroidogenesis, 42,43 and these data suggest a direct role within the pituitary.…”
Section: Discussionmentioning
confidence: 99%